Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 450-460

  Flowers, Stephanie A ^a   Colón, Brendan ^b   Whaley, Sarah G ^a   Schuler, Mary A ^b   David Rogers, P ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 REDUCTASE; FLUCONAZOLE; FUNGAL DNA; FUNGAL ENZYME; GENOMIC DNA; ITRACONAZOLE; PYRROLE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; VORICONAZOLE; ANTIFUNGAL AGENT; STEROL 14ALPHA DEMETHYLASE INHIBITOR;

ALLELE; AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; FUNGAL GENE; FUNGAL STRAIN; FUNGUS GROWTH; GENE MAPPING; GENE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PROMOTER REGION; SEQUENCE ANALYSIS; STATIC ELECTRICITY; CANDIDIASIS; DRUG EFFECTS; ENZYME ACTIVE SITE; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR GENETICS;

14-ALPHA DEMETHYLASE INHIBITORS; AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS; CATALYTIC DOMAIN; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; STEROL 14-DEMETHYLASE; VORICONAZOLE;

EID: 84920178124     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03470-14     Document Type: Article

References (45)

1. Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. 2012. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance) registry, 2004-2008. Diagn Microbiol Infect Dis 74:323-331. http://dx .doi.org/10.1016/j.diagmicrobio.2012.10.003.
2. Thompson GR, III, Patel PK, Kirkpatrick WR, Westbrook SD, Berg D, Erlandsen J, Redding SW, Patterson TF. 2010. Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109:488-495. http://dx.doi.org/10.1016/j.tripleo.2009 .11.026.
3. Patel PK, Erlandsen JE, Kirkpatrick WR, Berg DK, Westbrook SD, Louden C, Cornell JE, Thompson GR, Vallor AC, Wickes BL, Wiederhold NP, Redding SW, Patterson TF. 2012. The changing epidemiology of oropharyngeal candidiasis in patients with HIV/AIDS in the era of antiretroviral therapy. AIDS Res Treat 2012:262471. http://dx.doi.org/10 .1155/2012/262471.
4. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE. 1995. Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol. Biochem Biophys Res Commun 207:910-915. http://dx.doi.org/10.1006/bbrc.1995 .1272.
5. Warrilow AG, Martel CM, Parker JE, Melo N, Lamb DC, Nes WD, Kelly DE, Kelly SL. 2010. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother 54:4235-4245. http://dx.doi.org/10.1128/AAC.00587-10.
6. Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, Morschhauser J, Rogers PD. 2012. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot Cell 11:1289-1299. http://dx.doi.org /10.1128/EC.00215-12.
7. Selmecki A, Forche A, Berman J. 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313:367-370. http: //dx.doi.org/10.1126/science.1128242.
8. Selmecki A, Gerami-Nejad M, Paulson C, Forche A, Berman J. 2008. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol 68:624-641. http://dx.doi.org /10.1111/j.1365-2958.2008.06176.x.
9. Warrilow AG, Mullins JG, Hull CM, Parker JE, Lamb DC, Kelly DE, Kelly SL. 2012. S279 point mutations in Candida albicans sterol 14-alpha demethylase (CYP51) reduce in vitro inhibition by fluconazole. Antimicrob Agents Chemother 56:2099-2107. http://dx.doi.org/10.1128/AAC .05389-11.
10. Kelly SL, Lamb DC, Kelly DE. 1999. Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem.FEMSMicrobiol Lett 180:171-175. http://dx.doi .org/10.1111/j.1574-6968.1999.tb08792.x.
11. Kelly SL, Lamb DC, Loeffler J, Einsele H, Kelly DE. 1999. The G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun 262:174-179. http://dx.doi.org/10.1006 /bbrc.1999.1136.
12. Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W, Borgers M, Ramaekers FC, Odds FC, Bossche HV. 1999. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145:2701-2713.
13. Morio F, Loge C, Besse B, Hennequin C, Le Pape P. 2010. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azolesusceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 66:373-384. http://dx .doi.org/10.1016/j.diagmicrobio.2009.11.006.
14. Sanglard D, Ischer F, Koymans L, Bille J. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 42:241-253. http://dx.doi.org/10.1093/jac/42.2.241.
15. Reuss O, Vik A, Kolter R, Morschhäuser J. 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341:119-127. http://dx.doi.org/10.1016/j.gene.2004.06.021.
16. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved method M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Baudry J, Rupasinghe S, Schuler MA. 2006. Class-dependent sequence alignment strategy improves the structural and functional modeling of P450s. Protein Eng Des Sel 19:345-353. http://dx.doi.org/10.1093/protein /gzl012.
18. Rupashinghe SG, Schuler MA. 2006. Homology modeling of plant cytochrome P450s. Phytochem Rev 5:473-505. http://dx.doi.org/10.1007/s11101 -006-9028-y.
19. Henikoff S, Henikoff JG. 1992. Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A 89:10915-10919. http://dx.doi .org/10.1073/pnas.89.22.10915.
20. Monk BC, Tomasiak TM, Keniya MV, Huschmann FU, Tyndall JD, JD O'Connell, III, Cannon RD, McDonald JG, Rodriguez A, Finer-Moore JS, Stroud RM. 2014. Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer. Proc Natl Acad Sci U S A 111:3865-3870. http://dx.doi.org/10 .1073/pnas.1324245111.
21. MacKerell AD, Jr, Bashford D, Bellot M, Dunbrack RL, Jr, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, III, Roux B, Schlenkrich M, Smith JC, Stote R, Straub K, Watanabe M, Wiórkiewicz-Kuczera J, Yin D, Karplus M. 1998. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102:3586-3616. http://dx.doi.org/10 .1021/jp973084f.
22. Courcot B, Bridgeman AJ. 2011. Optimization of a molecular mechanics force field for type-II polyoxometalates focussing on electrostatic interactions: a case study. J Comput Chem 32:1703-1710. http://dx.doi.org/10 .1002/jcc.21752.
23. Halgren TA. 1996. Merck molecular force field. I. Basis, form, scope, parameterization and performance of MMFF94. J Comput Chem 17:490-519.
24. Sasse C, Dunkel N, Schäfer T, Schneider S, Dierolf F, Ohlsen K, Morschhäuser J. 2012. The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicans. Mol Microbiol 86:539-556. http://dx.doi.org/10.1111/j.1365-2958.2012.08210.x.
25. Lepesheva GI, Waterman MR. 2004. CYP51: the omnipotent P450. Mol Cell Endocrinol 215:165-170. http://dx.doi.org/10.1016/j.mce.2003.11.016.
26. Yoshida Y, Aoyama Y, Noshiro M, Gotoh O. 2000. Sterol 14-demethylase P450 (CYP51) provides a breakthrough for the discussion on the evolution of cytochrome P450 gene superfamily. Biochem Biophys Res Commun 273:799-804. http://dx.doi.org/10.1006/bbrc.2000.3030.
27. Nelson DR. 1999. Cytochrome P450 and the individuality of species. Arch Biochem Biophys 369:1-10. http://dx.doi.org/10.1006/abbi.1999.1352.
28. Lamb DC, Lei L, Warrilow AG, Lepesheva GI, Mullins JG, Waterman MR, Kelly SL. 2009. The first virally encoded cytochrome P450. J Virol 83:8266-8269. http://dx.doi.org/10.1128/JVI.00289-09.
29. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D, CLSI Subcommittee for Antifungal Susceptibility Testing. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 13: 180-195. http://dx.doi.org/10.1016/j.drup.2010.09.002.
30. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, Pfaller MA, Rinaldi M, Rodriguez-Tudela JL, Verweij PE. 2005. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 43: 3884-3889. http://dx.doi.org/10.1128/JCM.43.8.3884-3889.2005.
31. Alvarez-Rueda N, Fleury A, Morio F, Pagniez F, Gastinel L, Le Pape P. 2011. Amino acid substitutions at the major insertion loop of Candida albicans sterol 14alpha-demethylase are involved in fluconazole resistance. PLoS One 6:e21239. http://dx.doi.org/10.1371/journal.pone.0021239.
32. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 48:568-574. http://dx.doi.org/10.1128/AAC .48.2.568-574.2004.
33. Manavathu EK, Kallakuri S, Arganoza MT, Vázquez JA. 1999. Amino acid variations of cytochrome P-450 lanosterol 14 alpha-demethylase (CYP51A1) from fluconazole-resistant clinical isolates of Candida albicans. Rev Iberoam Micol 16:198-203.
34. Denisov IG, Shih AY, Sligar SG. 2012. Structural differences between soluble and membrane bound cytochrome P450s. J Inorg Biochem 108: 150-158. http://dx.doi.org/10.1016/j.jinorgbio.2011.11.026.
35. Sanglard D, Bille J. 2002. Action of and resistance to antifungal agents, p 370. In Calderone RA (ed), Candida and candidiasis. American Society for Microbiology, Washington, DC.
36. Favre B, Didmon M, Ryder NS. 1999. Multiple amino acid substitutions in lanosterol 14-demethylase contribute to azole resistance in Candida albicans. Microbiology 145:2715-2725.
37. Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Martínez M, Calabrese D, Sanglard D, Patterson TF. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45:2676 -2684. http://dx.doi.org/10.1128/AAC.45.10.2676 -2684.2001.
38. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. 2004. Application of real-time quantitativePCRto molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 48:2124 -2131. http://dx.doi.org/10.1128/AAC .48.6.2124-2131.2004.
39. Lee MK, Williams LE, Warnock DW, Arthington-Skaggs BA. 2004. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 53:217-224. http://dx.doi.org/10.1093/jac/dkh040.
40. Manastir L, Ergon MC, Yücesoy M. 2011. Investigation of mutations in Erg11 gene of fluconazole resistant Candida albicans isolates from Turkish hospitals. Mycoses 54:99-104. http://dx.doi.org/10.1111/j.1439-0507.2009.01766.x.
41. Xu Y, Chen L, Li C. 2008. Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J Antimicrob Chemother 61:798-804. http://dx.doi.org/10.1093/jac/dkn015.
42. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46: 1704 -1713. http://dx.doi.org/10.1128/AAC.46.6.1704 -1713.2002.
43. Li X, Brown N, Chau AS, López-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM. 2004. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 53:74-80. http://dx.doi.org /10.1093/jac/dkh027.
44. Löffler J, Kelly SL, Hebart H, Schumacher U, Lass-Flörl C, Einsele H. 1997. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett 151:263-268. http://dx.doi.org/10 .1016/S0378-1097(97)00172-9.
45. Kakeya H, Miyazaki Y, Miyazaki H, Nyswaner K, Grimberg B, Bennett JE. 2000. Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob Agents Chemother 44:2985-2990. http://dx .doi.org/10.1128/AAC.44.11.2985-2990.2000.